Singapore, May 9 -- Taiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with Almac Discovery, a Northern Ireland-based research driven drug discovery company, for exclusive rights to the commercialisation of ALM-401, a first-in-class, bispecific antibody drug conjugate (ADC) for the treatment of solid tumours characterised by the dual expression of EGFR and ROR1.

Almac Discovery focuses on protein homeostasis and next-generation antibody drug conjugates.

Their portfolio of preclinical and clinical stage drug candidates comprises both small and large molecule modalities, and benefits from collaboration and licensing partnerships with global R&D-focused biotech and pharmaceutical organizations. The licen...